Gilead adds to CAR-T assets with Cell Design Labs buyout – PMLiVE
PMLiVE |
Gilead adds to CAR–T assets with Cell Design Labs buyout
PMLiVE Gilead Sciences Just a few months after shelling out $12bn to buy CAR–T specialist Kite Pharma, Gilead Sciences is boosting its position in the category with a $567m swoop on Cell Design Labs (CDL). The new deal adds new technologies that could form … Gilead goes full throttle on CAR-Ts with $567m acquisition Look back at pharma news to Dec 8 |
